Amylin Pharmaceuticals

Investment firm

Amylin Pharmaceuticals

Corporate VC

Amylin Pharmaceuticals is a corporate venture arm. Based in San Diego, California, United States. Known portfolio companies include BioSeek and Xenome, 2 companies in all.

Is Amylin Pharmaceuticals a fit for your startup?

Paste your website. AI checks the fit and scores every other investor too.

Investment focus

Focus
BiotechCell-based ModelsDrug DiscoveryMedTechMetabolic DiseasePharma

Amylin Pharmaceuticals portfolio companies (2)

  • BioSeek
  • Xenome

Similar funds

Showing 20 of 100

About Amylin Pharmaceuticals

The firm's listing covers sector Healthcare, and focus areas Biotech, Cell-based Models, Drug Discovery and MedTech; known deals cluster at Growth and Seed.

Frequently asked questions

What is Amylin Pharmaceuticals?

Amylin Pharmaceuticals is a corporate venture arm based in San Diego, California, United States, with a known portfolio of 2 companies. The portfolio comes from public investment records rather than from the firm, so deals that never surfaced publicly are not in it.

What does Amylin Pharmaceuticals invest in?

Listed sectors include Healthcare; listed focus areas include Biotech, Cell-based Models, Drug Discovery and MedTech. Those tags come from the portfolio attached to the firm, so they describe what has been backed rather than a stated mandate for what comes next.

What stage does Amylin Pharmaceuticals invest at?

The known deals of Amylin Pharmaceuticals include Growth and Seed rounds. Check that against your own round before reaching out: stage mismatch is the most common reason a well matched sector still goes nowhere.

How do I contact Amylin Pharmaceuticals?

Any email address on file for the firm is masked on this page and readable inside RaiseHunt after you create an account.

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal